Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

Davidson, 2005, Chemoendocrine therapy for pre-menopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188), J Clin Oncol, 23, 5973, 10.1200/JCO.2005.05.551 Jonat, 2002, Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study, J Clin Oncol, 20, 4628, 10.1200/JCO.2002.05.042 Kaufmann, 2003, Survival analyses from the ZEBRA study: goserelin (Zoladex™) versus CMF in pre-menopausal women with node-positive breast cancer, Eur J Cancer, 39, 1711, 10.1016/S0959-8049(03)00392-7 Jakesz, 2002, J Clin Oncol, 20, 4621, 10.1200/JCO.2002.09.112 Baum, 2006, Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study, Eur J Cancer, 42, 895, 10.1016/j.ejca.2005.12.013 Castiglione-Gertsch, 2003, Adjuvant chemotherapy followed by goserelin versus either modality alone for pre-menopausal lymph node-negative breast cancer: a randomized trial, J Natl Cancer Inst, 95, 1833, 10.1093/jnci/djg119 von Minckwitz, 2006, CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in pre-menopausal patients: a randomised trial (GABG trial IV-A-93), Eur J Cancer, 42, 1780, 10.1016/j.ejca.2006.04.006 Wallwiener, 2004, A phase III trial comparing adjuvant treatment with leuprorelin acetate 3M-Depot for 24 months with CMF chemotherapy in ER/PR + node + pre-perimenopausal breast cancer patients, J Clin Oncol, 22, 533, 10.1200/jco.2004.22.14_suppl.533 Kaufmann, 2004, Goserelin versus control after adjuvant, risk-adapted chemotherapy in pre-menopausal patients with breast cancer. GABG trial IV-B-93, J Clin Oncol, 22, 588, 10.1200/jco.2004.22.14_suppl.588 Roché, 2006, Complete hormonal blockade versus epirubicin-based chemotherapy in pre-menopausal, one to three node-positive, and hormone receptor-positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial, Ann Oncol, 17, 1221, 10.1093/annonc/mdl107 Arriagada, 2005, Randomized trial of adjuvant ovarian suppression in 926 pre-menopausal patients with early breast cancer treated with adjuvant chemotherapy, Ann Oncol, 16, 389, 10.1093/annonc/mdi085 Boccardo, 2000, J Clin Oncol, 18, 2718, 10.1200/JCO.2000.18.14.2718 Mitsuyama, 2005, Assessment of goserelin treatment in adjuvant therapy for pre-menopausal patients with breast cancer in Japan—Zoladex breast cancer study group trial-B, Gan To Kagaku Ryoho, 32, 2071 De Placedo, 2005, A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer, Br J Cancer, 92, 467, 10.1038/sj.bjc.6602355 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0 Sharp, 1997, Sbe16: Meta-analysis, Stata Tech Bull, 38, 9 Falkson, 1991, Effect of chemotherapy with or without buserelin on serum hormone levels in pre-menopausal women with breast cancer, Eur J Cancer, 27, 1208, 10.1016/0277-5379(91)90082-O Petrek, 2006, Incidence, time course and determinants of menstrual bleeding after breast cancer treatment: a prospective study, J Clin Oncol, 24, 1045, 10.1200/JCO.2005.03.3969 2007, Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial, J Natl Cancer Inst, 99, 516, 10.1093/jnci/djk109 de Haes, 2003, Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated pre-menopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group, J Clin Oncol, 21, 4510, 10.1200/JCO.2003.11.064 Bernhard, 2007, The impact of adjuvant chemotherapy followed by goserelin versus either modality alone on amenorrhea, hot flushes and quality of life in pre-menopausal patients with lymph node-negative breast cancer: effect of age, J Clin Oncol, 25, 263, 10.1200/JCO.2005.04.5393 Gnant, 2004, Breast Cancer Res Treat, 88, S8 Francis, 2003, Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PgR+) breast cancer: the SOFT, TEXT, and PERCHE trials, Breast, 12, S44, 10.1016/S0960-9776(03)80143-1